Home
HelpTest Code EVROL Everolimus, Blood
Reporting Name
Everolimus, BUseful For
Managing everolimus immunosuppression in solid organ transplant
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
Whole Blood EDTASpecimen Required
Container/Tube: Lavender top (EDTA)
Specimen Volume: 3 mL
Collection Instructions:
1. Draw blood immediately before next scheduled dose.
2. Do not centrifuge.
3. Send whole blood specimen in original tube. Do not aliquot.
Additional Information: Therapeutic range applies to trough specimens collected immediately prior to a.m. dose.
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Whole Blood EDTA | Refrigerated (preferred) | 28 days | |
| Frozen | 28 days | ||
| Ambient | 14 days |
Reference Values
3-8 ng/mL
Target steady-state trough concentrations vary depending on the type of transplant, concomitant immunosuppression, clinical/institutional protocols, and time post-transplant. Results should be interpreted in conjunction with this clinical information and any physical signs/symptoms of rejection/toxicity.
Day(s) Performed
Monday through Sunday
CPT Code Information
80169
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| EVROL | Everolimus, B | 50544-6 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 35146 | Everolimus, B | 50544-6 |
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.Interpretation
Therapeutic targets vary by transplant site and institution protocol. Heart and kidney transplant guidelines suggest a therapeutic range of 3 to 8 ng/mL.
Measurement of drug concentrations in oncology chemotherapy is less common, thus no therapeutic range is established for this application.
Clinical Reference
1. Eisen HJ, Tuzcu EM, Dorent R, et al: Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349(9):847-858
2. Kovarik JM, Beyer D, Schmouder RL: Everolimus drug interactions: application of a classification system for clinical decision making. Biopharm Drug Dispos. 2006;27(9):421-426
3. Rothenburger M, Zuckermann A, Bara C, et al: Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference. J Heart Lung Transplant. 2007;26(4):305-311
4. Sanchez-Fructuoso AI: Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol. 2008;4(6):807-819
5. Milone MC, Shaw LM: Therapeutic drugs and their management. In: Rifai N, Horvath AR, Wittwer CT, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed. Elsevier; 2018:800-831
6.van Gelder T, Fischer L, Shihab F, Shipkova M: Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation. Transplant Rev (Orlando). 2017;31(3):151-157. doi:10.1016/j.trre.2017.02.007
Report Available
Same day/1 to 2 daysMethod Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Forms
If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
-Renal Diagnostics Test Request (T830)
-Therapeutics Test Request (T831)
Specimen Minimum Volume
1 mL